StockData

Endonovo Therapeutics, Inc. (ENDV) stock

ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $135.08KP/E –Yield –

Endonovo Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Endonovo Therapeutics's operating cash flow for the twelve months ending Sep 30, 2023 was -$629.90K. For fiscal 2022 it was -$678.84K. The highest annual figure on record is $8.50K in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$678.84K–
FY2021Dec 31, 2021-$986.58K–
FY2020Dec 31, 2020-$741.59K–
FY2019Dec 31, 2019-$2.54M–
FY2018Dec 31, 2018-$2.88M–
FY2017Dec 31, 2017-$2.99M–
FY2016Dec 31, 2016-$2.46M–
FY2015Dec 31, 2015-$1.02M–
FY2014Dec 31, 2014-$909.30K–
FY2013Dec 31, 2013-$257.42K–
FY2012Dec 31, 2012-$284.89K–
FY2011Dec 31, 2011-$50.35K-692.3%
FY2010Dec 31, 2010$8.50K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2023Sep 30, 2023-$65.37K–
Q2 FY2023Jun 30, 2023-$165.84K–
Q1 FY2023Mar 31, 2023-$173.16K–
Q4 FY2022Dec 31, 2022-$225.54K–
Q3 FY2022Sep 30, 2022-$123.86K–
Q2 FY2022Jun 30, 2022-$206.48K–
Q1 FY2022Mar 31, 2022-$122.95K–
Q4 FY2021Dec 31, 2021-$391.30K–
Q3 FY2021Sep 30, 2021-$169.41K–
Q2 FY2021Jun 30, 2021-$135.93K–
Q1 FY2021Mar 31, 2021-$289.95K–
Q4 FY2020Dec 31, 2020-$192.86K–
Q3 FY2020Sep 30, 2020-$96.67K–
Q2 FY2020Jun 30, 2020-$154.85K–
Q1 FY2020Mar 31, 2020-$297.22K–
Q4 FY2019Dec 31, 2019-$308.38K–
Q3 FY2019Sep 30, 2019-$1.02M–
Q2 FY2019Jun 30, 2019-$687.62K–
Q1 FY2019Mar 31, 2019-$528.23K–
Q4 FY2018Dec 31, 2018-$716.10K–
Q3 FY2018Sep 30, 2018-$830.38K–
Q2 FY2018Jun 30, 2018-$741.61K–
Q1 FY2018Mar 31, 2018-$590.75K–
Q4 FY2017Dec 31, 2017-$800.57K–
Q3 FY2017Sep 30, 2017-$841.36K–
Q2 FY2017Jun 30, 2017-$913.65K–
Q1 FY2017Mar 31, 2017-$434.19K–
Q4 FY2016Dec 31, 2016-$658.65K–
Q1 FY2016Jun 30, 2016-$1.03M–
Q1 FY2015Mar 31, 2015-$193.84K–
Q4 FY2014Dec 31, 2014-$227.73K–
Q3 FY2014Sep 30, 2014-$196.10K–
Q2 FY2014Jun 30, 2014-$289.53K–
Q1 FY2014Mar 31, 2014-$195.93K–
Q4 FY2013Dec 31, 2013-$53.67K–
Q3 FY2013Sep 30, 2013-$28.16K–
Q2 FY2013Jun 30, 2013-$59.36K–
Q1 FY2013Mar 31, 2013-$116.23K–

More Endonovo Therapeutics figures

See a number that looks wrong?